報價延遲最少15分鐘:2025/05/12 12:37 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.0936 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.54/-0.55
|
|
企業價值
25.04M
|
| 資產負債 |
|
每股賬面淨值
0.11
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/12 12:37 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. |